Neuroinflammation in cortical and meningeal pathology in multiple sclerosis: understanding from animal models by Silva, Berenice Anabel et al.
                                                                                                 www.nnjournal.net
Review Open Access




© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long 
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Neuroinflammation in cortical and meningeal 
pathology in multiple sclerosis: understanding from 
animal models
Berenice Anabel Silva1,2, Esteban Miglietta2, Carina Cintia Ferrari1,2
1Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB)- CONICET, Buenos Aires C1181ACH, Argentina.
2Leloir Institute Foundation, Institute for Biochemical Investigations, IIBBA- CONICET, Patricias Argentinas 435, Buenos Aires, 
C1405BWE, Argentina.
Correspondence to: Dr. Carina Cintia Ferrari, Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB)- CONICET, 
Potosi 4240, Buenos Aires C1181ACH, Argentina. E-mail: carinaferrari@gmail.com
How to cite this article: Silva BA, Miglietta E, Ferrari CC. Neuroinflammation in cortical and meningeal pathology in multiple 
sclerosis: understanding from animal models. Neuroimmunol Neuroinflammation 2020;7:[Online First]. 
http://dx.doi.org/10.20517/2347-8659.2020.47
Received: 19 Jun 2020    First Decision: 3 Aug 2020    Revised: 6 Sep 2020    Accepted: 16 Sep 2020    Available online: 11 Nov 2020
Academic Editor: Roberta Magliozzi    Copy Editor: Cai-Hong Wang    Production Editor: Jing Yu
Abstract
Multiple sclerosis (MS) is a neurodegenerative and inflammatory disease usually presenting with acute 
demyelinating events that can start as, or progress to, chronic damage. The development of animal experimental 
models, specific for each stage of MS will aid in the design of new drugs specific for the different forms of the 
disease. Animal models of experimental autoimmune encephalomyelitis successfully reflect the pathophysiological 
mechanisms of the early phases of MS. However, few models resemble the features of the progressive forms 
of MS such as cortical demyelination and meningeal inflammation. Recently, a few auspicious animal models 
recapitulating many of the characteristics of progressive MS, aimed at a better understanding of the pathology 
of these forms of the disease, have been developed. In this review, we will summarize the latest developments 
in animal models reflecting the cortical and meningeal pathological features of progressive MS, as well as their 
response to drugs specifically targeting these forms.
Keywords: Progressive multiple sclerosis, experimental autoimmune encephalomyelitis, cortex, grey matter, 
meningeal inflammation, adaptive immune response
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INTRODUCTION
Multiple sclerosis (MS) is a neurodegenerative and inflammatory disease of unknown etiology characterized 
by repeated inflammatory events, demyelination and axonal damage which cause loss of function in the 
central nervous system (CNS)[1]. MS displays different clinical patterns: recurrent episodes with periods of 
remission classified as relapsing-remitting MS (RRMS), which can progress to secondary progressive form 
(SPMS), or persistent progression from the onset of the disease classified as primary progressive MS (PPMS)
[2]. 
Even though MS was considered a disease that exclusively involved the white matter[3], it has been 
described to present neurodegenerative and demyelinating grey matter (GM) lesions, mostly located in 
the cortex[4]. These lesions can occur at early stages of the disease and worsen over time, contributing 
to the clinical disability and cognitive impairment in PPMS and SPMS[5-7]. Two theories tried to explain 
the relationship between cortical damage and meningeal inflammation; it was suggested that meningeal 
inflammation may play a role in the pathogenesis of cortical pathology (“outside-in” theory), but it is also 
plausible that cortical damage could induce meningeal inflammation (“inside-out” theory)[8]. 
Neuroinflammation and neurodegeneration play a key part in every stage of MS in all three forms of the 
disease (RRMS, PPMS, and SPMS)[9], but their exact role in each one is still debated[10,11]. For instance, 
anti-inflammatory and immunomodulatory treatments that are beneficial in the early stages of RRMS are 
ineffective in PPMS and SPMS where cortical damage and neurodegeneration are more prominent[9,12,13]. 
It has been previously demonstrated that immune cell infiltration and inflammation within the meninges 
correlate with the degree of GM demyelination, microglial activation, axonal pathology, and neuronal 
loss[14-16]. Neuronal loss within the motor cortex was associated with worse clinical progression such as the 
need of a wheelchair, longer disease duration, and younger age at death[17]. 
Here, we will review the available animal models related to cortical lesions and its associated meningeal 
inflammation from the PubMed database. Data related to the spinal cord or other brain regions are out 
of the scope of this review. The animal models of cortical and meningeal pathology reviewed here are 
summarized in Table 1 and Figure 1.
ANIMAL MODELS OF CORTICAL PATHOLOGY
The development of experimental animal models of MS is a key step towards clarifying the immune and 
pathological mechanisms of the progressive forms of this pathology and, in turn, advance the development 
new therapeutic approaches. Even though no single model represents all the pathophysiological 
characteristic of PPMS or SPMS, each one allows the study of different aspects of the disease. The ideal pre-
clinical animal model that represents the cortical damage of progressive MS should include GM pathology 
with chronic demyelination, neurodegeneration, neuroinflammation with innate and adaptive immune 
infiltrate, and glial activation[18,19].
Cortical inflammatory demyelinating lesions are considered a key feature of both PPMS and SPMS patients 
but are sparse in RRMS[20]. The mechanisms involved in cortical demyelination and neurodegeneration are 
still unknown. Therefore, the main challenge in MS therapeutics so far has been the difficulty of replicating 
the chronicity and injury pattern of SPMS and PPMS which are rather different from RRMS[18].
Experimental autoimmune encephalomyelitis (EAE) was developed 70 years ago and since then, it has 
greatly contributed to the study of MS pathophysiology, especially of RRMS. EAE was induced in rodents 
and monkeys, providing models of acute monophasic relapsing-remitting and chronic progressive 
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CNS inflammation (reviewed in[21]). Depending on the immunization agent, EAE can result in either a 
monophasic, relapsing-remitting, or even chronic disease. Therefore, based on the selected rodent strain, 
the immunogen, and the adjuvant, EAE can model different aspect of the disease. Spinal cord homogenate 
or purified antigens, including myelin basic protein, proteolipid protein (PLP), and myelin oligodendrocyte 
glycoprotein (MOG), induced acute monophasic EAE in Lewis and Dark Agouti rats[22-24]. Moreover, 
the immunization of SJL/J mice with PLP39-155 and PLP180-199 induced a form of RRMS. Additionally, 
immunization of Dark Agouti rats with MOG1-125, as well as of C57BL/6 mice with MOG35-55 peptide and 
BALB/c and C57BL/6 mice with PLP180-199 resulted in a chronic disease course, emulating the progressive 
forms of MS (reviewed in[24,25]). 
Despite its usefulness for studying RRMS, EAE has poorly contributed to the analysis of cortical lesions, 
demonstrating its limitations for studying the progressive forms of MS. Due to this situation, several animal 
models of focal cortical pathology of MS have emerged in recent years in order to address this gap in the 
knowledge. 
EAE is a model based on immune stimulation with myelin proteins, such as MOG or PLP, which induce 
CNS autoimmunity with infiltration of CD4+ and CD8+ B cells as well as monocytes[26]. Some EAE-based 
models were adapted to mimic focal cortical lesions. For example, one study induced chronic EAE in 
several strains of Lewis rats by active immunization with recombinant rat MOG1-125. In this study, cortical 
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Table 1. Animal models of cortical and meningeal pathology
EAE: experimental autoimmune encephalomyelitis; TNF-α: tumor necrosis factor-alpha; IFN-γ: interferon gamma; IL-1β: interleukin 
1beta; GM-CSF: granulocyte-macrophage colony-stimulating factor
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demyelination was dependent on particular combinations of MHC class I and II isotypes and alleles. These 
cortical lesions presented demyelination, microglial activation, and the deposition of immunoglobulins on 
myelin sheaths[27]. Other EAE-based models were modified to mimic cortical lesions by injecting a cocktail 
of cytokines, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ) in the cortex of MOG 
immunized animals. These lesions presented demyelination, neuroinflammation, glial activation, and 
neuronal degeneration[28-30]. However, each model exhibited some differences. In particular, Merkler et al.[30] 
developed a focal cortical model based on the stereotactical injection of TNF-α and IFN-γ in the cortex 
of rat MOG1-125 immunized Lewis rats. Thus, the authors generated demyelinated intracortical and 
subpial lesions with inflammatory cell infiltration (CD4+ T cells, CD8+ T cells, and ED1+ macrophages), 
deposition of complement proteins, axonal damage and neurodegeneration which were all resolved within 
14 days[30]. In another model, the cocktail of TNF-α and IFN-γ was injected in the intrathecal space of Dark 
Agouti rats immunized with a subclinical dose recombinant mouse MOG in incomplete Freund’s adjuvant. 
This design induced meningeal inflammation which is associated with cortical subpial demyelination and 
microglia/macrophage activation in a gradient from the pial surface to the deeper cortical layers, with 
no neurodegeneration, lasting for 14 days[31]. The meningeal infiltration included lymphocytes CD4+ and 
CD8+ T cells and CD79+ B cells along with extensive microglial/macrophage activation[31].
Other authors achieved a chronic cortical pathology by placing a catheter in the rodent’s cortex which 
allowed the reinjection of cytokines. Dark Agouti rats were subclinically immunized with a low dose of 
Figure 1. Schematic representation of cortical damage and meningeal inflammation in animal models. The meninges contain the 
cerebrospinal fluid, which includes T cells and B cells. Meningeal inflammation can appear either diffuse or forming follicle-like 
structures, which are associated with B cells. The animal models are mostly based on peripheral immunization with MOG or PLP 
peptides, which activate the innate and adaptive immune response, coupled with the intracortical injection of a cocktail of pro-
inflammatory cytokines (TNF-α and IFN-γ). Also, cortical damage can be developed by a single injection of IL-1β into the cortex. The 
peripheral immune cells cross the blood brain barrier into the central nervous system. Activated microglia and astroglia, induced by 
the pro-inflammatory environment within the cortex, induce demyelination and neurodegeneration. HN: healthy neuron; RA: resting 
astrocyte; RM: resting microglia; Tc: T cells; Bc: B cells; FLS: follicle-like structures; BBB: blood brain barrier; AM: activated microglia; 
AA: activated astroglia; DN: neurodegeneration; MOG: myelin oligodendrocyte glycoprotein; PLP: proteolipid protein
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MOG1-125 dissolved in incomplete Freund’s Adjuvant, then subsequent injections of TNF-α + IFN-γ were 
administered in the cortex using a catheter. The cortical and subcortical lesions presented inflammatory 
infiltrate (macrophages and T-cells), demyelination, microglia activation, neurodegeneration, and 
meningeal inflammation[32]. These demyelinated cortical lesions reached maximum size on days 9-15 and 
lasted for 30 days. Additionally, the cortical tissue showed upregulation of genes related to TNF-α signaling 
pathways involved in apoptosis/necrosis. In particular, the presence of neuronal loss and the upregulation 
of necroptosis signaling was demonstrated by the presence pRIPK3 and MLKM in cortical neurons[17].
The contribution of the immune mechanisms to cortical demyelination was also studied in several lines 
of transgenic mice, which showed that CCR2+ monocytes play a role in this process. One of these models 
was based on the intracerebral injection of a cocktail of cytokines (TNF-α and IFN-γ) in MOG-immunized 
transgenic mice. The authors demonstrated that transgenic mice with high titers of MOG-specific 
immunoglobulins in the serum (Th+) crossbreeding with CC chemokine receptor 2 (CCR2) deficient (Th/+ 
CCR2-/-) mice have less activated microglia (Mac-3+) perivascular cuffing, diminished mRNA levels of 
TNF-α and iNOS (monocytes-related genes) and reduced subpial and cortical demyelination compared to 
controls. In addition, the authors studied the depletion of CCR2+ monocytes in the common marmoset by 
administrating DOC-2 Fr-2 (a marmoset IgG1-chimeric humanized mouse anti-human CCR2 antibody) 
twice a week. The depletion was performed 14 days after the immunization of the marmoset with rat 
MOG1-125. Monocyte-depleted animals exhibited less cortical and perivascular demyelination along with 
an improved clinical disease course. Thus, the author proposed that CCR2+ monocytes are required for 
triggering cortical demyelination[29]. 
We have developed a new animal model of cortical pathology based on the innate immune response 
achieved by the long-term expression of interleukin 1beta (IL-1β) in the rat cortex, along with peripheral 
inflammation. IL-1β injected rats presented neuroinflammation (with neutrophil and monocyte 
infiltration), demyelination, neurodegeneration, meningeal inflammation and upregulation of pro-
inflammatory cytokine mRNAs for IL-1β, TNF-α, and IL-6. These pathological features induced cognitive 
impairment and anxiety-like symptoms in IL-1β injected animals compared to controls. The cortical lesions 
could be visualized by MRI and the symptoms remained for almost 50 days, demonstrating that it is a 
chronic model of MS[33]. 
An EAE model induced by recombinant rat MOG-immunized marmosets along with stereotactic injection 
of cytokines (TNF-α and IFN-γ) was proposed as an intermediate step between pre-clinical and clinical 
trials[28,34]. This experimental design induced two types of lesions: (1) large demyelinating lesions like those 
found in human MS patients; and (2) perivascular foci of demyelination. These lesions contained CD3+ 
T cells and reactive GFAP+ astroglia. The macrophages expressed the myeloid-related protein-14 as well 
as myelin proteins such as 2’,3’-cyclic-nucleotide-3’-phosphodiesterase and MOG, which are observed 
in active human MS lesions. Numerous OLIG2+ cells were observed in the demyelinating areas, thus 
demonstrating the presence of oligodendrocyte precursor cells. Additionally, APP+ degenerating axons 
could be observed within the demyelinating lesions. These cortical lesions could be observed by MRI two 
weeks after the injection of the cytokines. Together with previous data, the authors concluded that the 
histopathology of the lesions developed in marmoset resembles early active human MS[28]. Another model 
induced cortical grey matter demyelinating lesions by immunizing marmosets with human MOG34-56 in 
incomplete Freund’s adjuvant. This model is based on the activation of adaptive immune mechanisms, 
the antigen-experienced T and/or B cells response. The pathology of the lesions in the cortex included 
demyelination, microglial activation, oxidative stress, and redistribution of iron[35,36]. Similar results 
were obtained if the marmosets were immunized using rat MOG1-125, which induce Type II MS pattern 
subcortical white matter lesions[30]. 
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As it was previously stated, the mechanisms that mediate the pathogenesis of subpial lesions remain 
uncertain. However, it has been proposed that the inflammation of the overlying meninges could be linked 
to subpial injury. Based on this hypothesis, Ward et al.[37] showed in a non-focal EAE model that adoptive 
transfer of PLP-primed Th17+ cells into recipient SJL/J mice induced subpial demyelination associated with 
microglial/macrophage activation, disruption of the glia limitans as well as an oxidative stress response. 
This pathology was topologically associated with foci of immune cells in the meninges and occurred in the 
absence of measurable anti-MOG IgM or IgG antibodies.
ANIMAL MODELS OF MENINGEAL INFLAMMATION 
The meningeal inflammation found in MS patients is a hallmark of the progressive forms of MS which 
contributes to the chronification of the cortical pathology. This knowledge required the development of 
specific animal models. 
Cortical lesions have been associated with increased meningeal inflammation, which can be either diffuse 
or, more often, be organized in lymphoid-like tissue associated to grey matter pathology, leading to a more 
severe and rapid disease progression in MS patients[14-16,38]. Follicular-like structures (FLS) have recently 
been found in the meninges, specifically in the subarachnoid space, of SPMS patients and several animal 
models. FLS appear at different stages of development, from clusters of cells to highly organized follicles[14]. 
These structures contain proliferating B lymphocytes, plasma cells, mesenquimal cells, T lymphocytes and a 
network of follicular dendritic cells[39]. Chemokines and lymphotoxins, including CXCL13, CCL19, CCL21, 
CXCL12 and B cell activating factor (BAFF), influence the organization of B cells inside the follicles[40]. 
These follicular structures were areas of B-cell reactivation and antibody production, which suggests that 
soluble factors might diffuse into the cortex and induce cortical damage[14,15,41,42]. 
However, the exact relationship between these follicular meningeal structures and disease progression 
is not yet fully understood[43]. A very early study demonstrated the presence of similar FLS containing B 
cells, T cells and dendritic cells in the meninges of SJL/J mice with EAE[44]. Following that seminal study, 
several researchers started investigating the presence of follicle-like structures in different types of EAE 
immunization[42,45-47]. We will review the most outstanding data that correlates the presence of meningeal 
inflammation with cortical damage.
SJL/J mice immunized with PLP139-151 peptide developed meningeal B cell follicles. The expression of 
lymphotoxins was essential for lymphoid tissue organization in this model of relapsing-remitting EAE, 
while the blockage of the lymphotoxin pathway inhibited the formation of FLS, reduced T and B cell 
infiltration and prevented the expression of chemokines such as CXCL10 and CXCL13[42]. Moreover, the 
presence of IL-17, IL-22, and lymphotoxin beta was described in the FLS of SJL/J mice immunized with 
PLP139-151 in an emulsion of complete Freund’s adjuvant
[45]. On the other hand, a model of non-obese 
diabetic mouse strain demonstrated the occurrence of meningeal inflammation, mostly composed of 
B cells, without the presence of FLS[46]. Similarly, meningeal inflammation in mice with MOG-induced 
EAE was characterized by sporadic distribution of cells expressing CD45 and CD19, clusters of Iba1+ 
macrophages and lesions that could be visualized by a 9.4 tesla MRI scanner[48].
Meningeal and subpial brain pathology were also described in a model of subclinical MOG-induced EAE, 
driven by adoptive transfer of PLP-primed Th17+ lymphocytes, which induced subpial demyelination, 
microglial/macrophage activation and oxidative stress[37]. In a Dark Agouti rat model of subclinical 
MOG-induced EAE with persistent infusion of a lentiviral vector expressing TNF-α and IFN-γ in the 
meninges, the authors demonstrated the presence of cortical pathology together with activation of TNF-α 
signaling pathways in cortical cells, leading to neuronal death and subpial demyelination. The meningeal 
inflammatory infiltrate was mostly composed of densely packed CD4+ T cells, CD8+ T cells and CD79+ 
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B cells filling the subarachnoid space, which lasted for 56 days[16]. CD4+ and CD8+ T cells were roughly 
evenly distributed throughout the subarachnoid space, but CD79a+ B cells appeared to form discrete 
clusters. However, data demonstrated no features of lymphoid-like tissues in these clusters[17].
Even though most animal models for the study of meningeal FLS were based on EAE induction, our novel 
rat model of focal cortical inflammation, generated by the long-term expression of IL-1β in the cortex, also 
induced meningeal inflammation with FLS. These structures contained CD4+, CD8+, CD20+, CD23+ and 
CD39+ cells and were associated with cortical demyelination and neurodegeneration along with anxiety-
like symptoms and short-term memory deterioration. Additionally, these cortico-meningeal structures 
could be visualized by MRI with gadolinium contrast[33]. 
Until now, the animal models described previously have represented the first step towards modelling the 
meningeal pathology associated with cortical damage. The development of a variety of animal models that 
mimic most of the characteristics of meningeal inflammation may help answer questions on the effect of 
the meninges in cortical tissue damage and, in turn, the effect of cortical damage on the inflammatory 
events occurring in the meninges.
EFFECT OF THERAPEUTIC AGENTS ON ANIMAL MODELS OF CORTICAL AND MENINGEAL 
ANIMAL MODELS 
Although cortical pathology is important for the prognosis of patients, no new treatments have been 
specifically designed to target this aspect of disease. Thus, the evidence that some currently available drugs 
can also target cortical pathology provides valuable aid to the treatment of MS patients while waiting for 
the development of specific therapies targeting cortical pathology. A few previously approved drugs have 
already been tested in animal models of cortical pathology with the aim of showing their efficacy in cortical 
MS pathology, among them siponimod, glatiramer acetate and laquinimod. 
Siponimod (BAF312) is a novel sphingosine-1-phosphate receptor modulator demonstrated to delay 
progression in PMS. The drug was recently approved by the United States Food and Drug Administration 
and the European Medicines Agency[37,49]. It was proposed that siponimod could reduce inflammation by 
sequestering lymphocytes in lymphoid tissues and could cross the blood-brain barrier by binding to its 
receptors on neurons, astrocytes and oligodendrocytes[50]. Siponimod was tested in a cortical model of 
MOG35-55EAE C57BL/6J mice with the addition of intracortical administration of a cocktail of cytokines 
(TNF-α and IFN-γ). The authors demonstrated that demonstrated that oral, but not intracerebral, 
administration of siponimod diminished the infiltration of immune cells within both grey and white 
matter lesions. Siponimod administration partially restored cortical neuronal circuit function by exerting a 
neuroprotective effect after crossing the blood-brain barrier[49]. Moreover, the administration of siponimod 
significantly ameliorated subclinical MOG-induced EAE symptoms and improved subpial pathology 
concomitantly with selective reduction in the capacity of transferred T cells to induce Th17 cytokines[37]. In 
addition, they demonstrated that siponimod impaired the formation of meningeal tertiary lymphoid tissue, 
although it did not completely prevent the associated clinical symptoms of EAE. Siponimod diminished 
fibronectin network formation in the meninges by about 47% compared to control mice. The accumulation 
of B220+ and CD3+ cells was also significantly decreased compared to control animals, possibly due to the 
lack of fibronectin matrix support which is necessary for tertiary lymphoid tissue formation[37].
Glatiramer acetate is an immunomodulatory drug for RRMS that was demonstrated to have neuroprotective 
effects in two different EAE models, relapsing-remitting PLP-induced EAE disease and chronic MOG-
induced EAE disease. The administration of glatiramer acetate alleviated cognitive impairment and cortico/
hippocampal damage in these animals by downregulating pro-inflammatory pathways[51]. In addition, 
glatiramer acetate treatment in MOG35-55-induced EAE mice potentiated neuroprotection by incrementing 
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neurotrophic factors (BDNF, NT-3, and NT-4)[51-53]. Additionally, BDNF expression in glatiramer acetate 
treated mice induced the differentiation/proliferation of neuronal progenitors that migrated into lesions 
in injured regions. These results indicate that the immunomodulator glatiramer acetate exerts anti-
inflammatory, neuroprotective and regenerative effects in the diseased brain[52]. 
Laquinimod is a quinoline-3-carboxamide derivative that was demonstrated to inhibit the development of 
disease in inflammatory mouse models for MS such as EAE[54-56]. A focal model based on the combination 
of EAE induced with rat recombinant MOG, together with the injection of TNF-α and IFN-γ in the cortex 
and corpus callosum of the common marmoset, presented leukocortical demyelinating lesions at the site 
of the injections in both white and gray matter, as previously described. The prophylactic treatment with 
laquinimod completely prevented the leuko-cortical lesion formation in this model. The cortex of animals 
treated with laquinimod presented a lack of demyelinating lesions which could not be detected by MRI, and 
minor astrocytic and microglial reaction at the injection site. Thus, prophylactic modulation of the immune 
system by laquinimod prevents the development of focal EAE in marmoset[28]. Additionally, laquinimod 
demonstrated immunosuppressive and neuroprotective properties in a model based on a combination of 
neurodegeneration induced by cuprizone feeding and MOG35-55-induced EAE in mice, which provokes an 
infiltration of myelin autoreactive T cells from peripheral lymphoid organs. The treatment with laquinimod 
was suspended two weeks prior to active EAE induction. Laquinimod ameliorated cuprizone pathology 
reduced demyelination, axonal loss, and microglial and astroglial activation but, at the same time, it 
decreased peripheral immune cell recruitment, particularly of lymphocytes[54-56]. This study demonstrated 
that ameliorating a primary degenerative CNS process might reduce the secondary inflammatory lesion 
development[56].
CONCLUSION
Grey matter lesions and meningeal inflammation are two of the most outstanding features of the 
progressive forms of MS and of RRMS, resulting in higher disease activity and poorer outcome. Animal 
models provide valuable insight into the knowledge of the role of cortical damage and its association with 
meningeal inflammation in MS. They also collaborated with the identification of the immune cells and 
molecules such as specific cytokines and chemokines involved in the development of cortical damage 
and meningeal inflammation pathologic processes. In addition, animal models helped to understand how 
immune molecules, either from cells within the cortex or from the inflammatory events in the meninges, 
impact glial activation, axonal degeneration, and oligodendrocyte death. Even though it was suggested that 
meningeal inflammation may play a role in the pathogenesis of cortical pathology (“outside-in” theory), it 
is also plausible that cortical damage induces meningeal inflammation (“inside-out” theory). In order to 
address this dichotomy, we need new information from animal models. 
The importance of good preclinical studies is highlighted by the fact that research with animal models has 
already led to the development of three approved therapies for use in MS. However, most new therapeutic 
drugs showing promise in the preclinical studies end up failing in the clinical practice. One of the reasons 
that might explain this is the lack of development or evaluation of suitable animal models of MS. Still, there 
is no specific MS model that allows to study the entire pathology of the disease; several models reflecting 
the different aspects of the disease are available. The election of the right model to answer a specific 
question should be done in accordance with the specific aims of the study. 
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